A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

首次发布于 2022 年 12 月 14 日

A Study Explore JS001+JS002 in Patients With Advanced Cancer

计划入组 9 人 · 首次发布于 2021 年 11 月 22 日

A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector

计划入组 272 人 · 首次发布于 2024 年 12 月 13 日

TAB006/JS006

JS006

TNM009

Junshi Biosciences' Anti-CD112R Monoclonal Antibody, TAB009/JS009, Receives FDA IND Approval for Advanced Solid Tumors

Junshi Biosciences' IL-17A Inhibitor JS005 Meets Primary Endpoints in Phase 3 Psoriasis Trial

TC BioPharm Initiates Preclinical Studies for TCB008 Targeting H5N1 Bird Flu